OBJECTIVES: This study sought to evaluate feasibility of nonsurgical transthoracic catheter-based left ventricular (LV) access and closure. BACKGROUND: Implanting large devices, such as mitral or aortic valve prostheses, into the heart requires surgical exposure and repair. Reliable percutaneous direct transthoracic LV access and closure would allow new nonsurgical therapeutic procedures. METHODS: Percutaneous direct LV access was performed in 19 swine using real-time magnetic resonance imaging (MRI) and an "active" MRI needle antenna to deliver an 18-F introducer sheath. The LV access ports were closed percutaneously using a commercial ventricular septal defect occluder and an "active" MRI delivery cable for enhanced visibility. We used "permissive pericardial tamponade" (temporary fluid instillation to separate the 2 pericardial layers) to avoid pericardial entrapment by the epicardial disk. Techniques were developed in 8 animals, and 11 more were followed up to 3 months by MRI and histopathology. RESULTS: Imaging guidance allowed 18-F sheath access and closure with appropriate positioning of the occluder inside the transmyocardial tunnel. Of the survival cohort, immediate hemostasis was achieved in 8 of 11 patients. Failure modes included pericardial entrapment by the epicardial occluder disk (n = 2) and a true-apex entry site that prevented hemostatic apposition of the endocardial disk (n = 1). Reactive pericardial effusion (192 ± 118 ml) accumulated 5 ± 1 days after the procedure, requiring 1-time drainage. At 3 months, LV function was preserved, and the device was endothelialized. CONCLUSIONS: Direct percutaneous LV access and closure is feasible using real-time MRI. A commercial occluder achieved hemostasis without evident deleterious effects on the LV. Having established the concept, further clinical development of this approach appears realistic.
OBJECTIVES: This study sought to evaluate feasibility of nonsurgical transthoracic catheter-based left ventricular (LV) access and closure. BACKGROUND: Implanting large devices, such as mitral or aortic valve prostheses, into the heart requires surgical exposure and repair. Reliable percutaneous direct transthoracic LV access and closure would allow new nonsurgical therapeutic procedures. METHODS: Percutaneous direct LV access was performed in 19 swine using real-time magnetic resonance imaging (MRI) and an "active" MRI needle antenna to deliver an 18-F introducer sheath. The LV access ports were closed percutaneously using a commercial ventricular septal defect occluder and an "active" MRI delivery cable for enhanced visibility. We used "permissive pericardial tamponade" (temporary fluid instillation to separate the 2 pericardial layers) to avoid pericardial entrapment by the epicardial disk. Techniques were developed in 8 animals, and 11 more were followed up to 3 months by MRI and histopathology. RESULTS: Imaging guidance allowed 18-F sheath access and closure with appropriate positioning of the occluder inside the transmyocardial tunnel. Of the survival cohort, immediate hemostasis was achieved in 8 of 11 patients. Failure modes included pericardial entrapment by the epicardial occluder disk (n = 2) and a true-apex entry site that prevented hemostatic apposition of the endocardial disk (n = 1). Reactive pericardial effusion (192 ± 118 ml) accumulated 5 ± 1 days after the procedure, requiring 1-time drainage. At 3 months, LV function was preserved, and the device was endothelialized. CONCLUSIONS: Direct percutaneous LV access and closure is feasible using real-time MRI. A commercial occluder achieved hemostasis without evident deleterious effects on the LV. Having established the concept, further clinical development of this approach appears realistic.
Authors: Israel M Barbash; Christina E Saikus; Kanishka Ratnayaka; Anthony Z Faranesh; Ozgur Kocaturk; Vincent Wu; Jamie A Bell; William H Schenke; Venkatesh K Raman; Robert J Lederman Journal: Catheter Cardiovasc Interv Date: 2011-03-21 Impact factor: 2.692
Authors: June-Hong Kim; Ozgur Kocaturk; Cengizhan Ozturk; Anthony Z Faranesh; Merdim Sonmez; Smita Sampath; Christina E Saikus; Ann H Kim; Venkatesh K Raman; J Andrew Derbyshire; William H Schenke; Victor J Wright; Colin Berry; Elliot R McVeigh; Robert J Lederman Journal: J Am Coll Cardiol Date: 2009-08-11 Impact factor: 24.094
Authors: S C Brown; D E Boshoff; F Rega; B Eyskens; W Budts; H Heidbüchel; B Meyns; M Gewillig Journal: Catheter Cardiovasc Interv Date: 2009-07-01 Impact factor: 2.692
Authors: N Gudino; M Sonmez; Z Yao; T Baig; S Nielles-Vallespin; A Z Faranesh; R J Lederman; M Martens; R S Balaban; M S Hansen; M A Griswold Journal: Med Phys Date: 2015-01 Impact factor: 4.071
Authors: Kanishka Ratnayaka; Anthony Z Faranesh; Michael S Hansen; Annette M Stine; Majdi Halabi; Israel M Barbash; William H Schenke; Victor J Wright; Laurie P Grant; Peter Kellman; Ozgur Kocaturk; Robert J Lederman Journal: Eur Heart J Date: 2012-08-01 Impact factor: 29.983
Authors: Sophie C Rier; Suzan Vreemann; Wouter H Nijhof; Vincent J H M van Driel; Ivo A C van der Bilt Journal: Ther Adv Cardiovasc Dis Date: 2022 Jan-Dec
Authors: Majdi Halabi; Kanishka Ratnayaka; Anthony Z Faranesh; Michael S Hansen; Israel M Barbash; Michael A Eckhaus; Joel R Wilson; Marcus Y Chen; Michael C Slack; Ozgur Kocaturk; William H Schenke; Victor J Wright; Robert J Lederman Journal: J Cardiovasc Magn Reson Date: 2013-01-18 Impact factor: 5.364